News | December 03, 2006

Docs Should Alert ICD/Pacemaker Patients About Magnets

Magnets may interfere with the operation of pacemakers and implantable cardioverter defibrillators (ICDs), according to a study published in the December 2006 edition of “Heart Rhythm.”

A release from the Heart Rhythm Society reports that researchers found that while common magnets for home and office use with low magnetic strength posed little risk, stronger magnets made from neodymium-iron-boron (NdFeB) may cause interference with cardiac devices and pose potential hazards to patients. NdFeB magnets are increasingly being used in homes and office products, toys, jewelry and even clothing.

“Physicians should caution patients about the risks associated with these magnets,” says Thomas Wolber, a cardiologist at the University Hospital of Zurich in Switzerland and lead author of the study. “We also recommend that the packaging include information on the potential risks that may be associated with these types of magnets.”

Two spherical magnets of eight and 10 millimeters in diameter and one necklace made of 45 spherical magnets were tested on 70 patients, 41 with pacemakers and 29 with ICDs. Magnetic interference was observed in all patients. The cardiac devices resumed normal function after the magnets were removed.

“This study is timely and important to attract the attention of both the public and the medical profession about the potentially serious health consequences of magnets used in decoration products... for an ICD patient, the magnet interference can be fatal,” writes Huagui Li, M.D., a cardiologist at the Minnesota Heart Clinic in Edina, MN, in an accompanying “Heart Rhythm” editorial.

Dr. Li concludes that manufacturers who use magnets should be required to put warning labels on their products for optimal patient safety.


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now